Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
1996-04-08
2002-10-22
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S155100, C424S159100, C424S181100, C424S183100
Reexamination Certificate
active
06468530
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel polyspecific immunoconjugates that are useful for diagnosis and therapy of diseases caused by cells that are multidrug resistant. In particular, this invention relates to polyspecific immunoconjugates that comprise at least one moiety that binds with a multidrug transporter protein, at least one moiety that binds with a tumor associated antigen or infectious agent antigen, and a therapeutic or diagnostic agent. This invention also relates to methods of diagnosis and therapy using the polyspecific immunoconjugates. This invention further relates to diagnostic and therapeutic uses of antibody composites comprising at least one moiety that binds with a multidrug transporter protein, and at least one moiety that binds with a tumor associated antigen or infectious agent antigen.
2. Background
One of the major limitations of cancer chemotherapy is the development of drug resistance by cancer cells. Despite initial sensitivity to a particular chemotherapeutic agent, some tumors become progressively unresponsive to the particular agent, or to various chemotherapeutic agents. This phenomenon of acquired drug resistance is believed to be due to the selection and growth of drug resistant mutant tumor cells. See, for example, Deuchars et al.,
Sem. Oncol.
16: 156 (1989).
Cultured cell lines and transplantable tumors have been used to study the mechanism of acquired drug resistance in vitro. These studies have shown that under certain selection conditions, cells may acquire simultaneous resistance to a diverse group of drugs that are unrelated to the selecting agent in structure, cellular target and mode of action. See, for example, Bradley et al.,
Biochim. Biophys. Acta
948: 87 (1988); Deuchars et al., supra. Many of the drugs affected by this “multidrug-resistance” (MDR) phenotype are important in current treatment protocols, such as vincristine, actinomycin D., and adriamycin. Id.
The MDR phenotype is consistently associated with over-expression of a 170 kilodalton membrane glycoprotein, designated “gp170” or “P-glycoprotein.” Endicott et al.,
Ann. Rev. Biochem.
58: 137 (1989); Kane et al.,
J. Bioenerg. Biomembr.
22: 593 (1990); Efferth et al.,
Urol. Res.
18: 309 (1990). Studies indicate that P-glycoprotein is a transmembrane protein responsible for an ATP-dependent efflux of a broad spectrum of structurally and functionally distinct drugs from multidrug-resistant cells. Riordan et al.,
Pharmacol. Ther.
28: 51 (1985). In fact, expression of P-glycoprotein has been shown to be predictive of a poor response to chemotherapy in a number of neoplasms. See, for example, Pearson et al.,
J. Nat'l Cancer Inst.
83: 1386 (1991).
Recent observations indicate that infectious agents can induce the MDR phenotype in noncancerous cells. For example, prolonged treatment with 3′-azido-3′-deoxythymidine (AZT) for human immunodeficiency virus (HIV) infection is associated with an acquired resistance to AZT. Gollapudi et al.,
Biochem. Biophys. Res. Commun.
171: 1002 (1990); Antonelli et al.,
AIDS Research and Human Retroviruses
8: 1839 (1992). In vitro studies demonstrate that. HIV-infected human cells have an increased expression of P-glycoprotein and accumulate less AZT, compared with non-infected control cells. Id.; Gupta et al.,
J. Clin. Immunol.
13: 289 (1993). Thus, overexpression of P-glycoprotein and the accompanying MDR phenotype can impair chemotherapy with anti-viral drugs.
Considerable effort has been employed to overcome the multidrug-resistant phenotype and thus, improve the efficacy of chemotherapy. Most of these strategies have involved pharmacological agents that enhance the intracellular accumulation of the cancer drugs by biochemically inhibiting the multidrug transporter. See, for example, Ford et al.,
Pharmacol. Rev.
42: 155 (1990). Examples of agents that modulate P-glycoprotein activity include calcium channel blockers, calmodulin inhibitors, antiarrythmics, antimalarials, various lysoosmotropic agents, steroids, antiestrogens, and cyclic peptide antibiotics. Rittmann-Grauer et al.,
Cancer Res.
52: 1810 (1992).
However, multidrug-resistant reversing drugs used in early clinical trials have shown major side effects unrelated to the inhibition of P-glycoprotein, such as cardiac toxicity (verapamil) or immunosuppression (cyclosporin A), which limit the dosage of drug that can be administered. See, for example, Ozols et al.,
J. Clin. Oncol.
5: 641 (1987); Dalton et al.,
J. Clin. Oncol.
7: 415 (1989); Cano-Gauci et al.,
Biochem. Pharmacol.
36: 2115 (1987); Ford et al., supra. Thus, there has been limited success in reversing MDR in vivo due to the toxicity of many of these small modulators. See, for example, Rittmann-Grauer et al., supra.
The use of antibody-drug conjugates provides an alternative approach to overcoming the MDR phenotype. For example, in vitro studies have shown that MDR can be partially overcome by conjugating the resistant drug to an antitumor antibody to increase uptake and subsequent cell death. Durrant et al.,
Brit. J. Cancer
56: 722 (1987); Sheldon et al.,
Anticancer Res.
9: 637 (1989). This approach, however, lacks specificity for tumor cells that express the MDR phenotype.
A more targeted approach to overcoming the MDR phenotype is to use antibodies or antibody conjugates that bind with P-glycoprotein. For example, the administration of an anti-P-glycoprotein monoclonal antibody and a resistant drug can increase the survival time of nude mice that carry human tumor cells. Pearson et al.,
J. Nat'l Cancer Inst.
83: 1386 (1991); Iwahashi et al.,
Cancer Res.
53: 5475 (1993). Also, see Grauer et al., international publication No. WO 93/02105 (1993). In addition, an anti-P-glycoprotein monoclonal antibody-Pseudomonas toxin conjugate has been shown to kill multidrug-resistant human cells in vitro. FitzGerald et al.,
Proc. Nat'l Acad. Sci. USA
84: 4288 (1987). Also, see Efferth et al.,
Med. Oncol.
&
Tumor Pharmacother.
9: 11 (1992), and Mechetner et al., international publication No. WO 93/19094 (1993).
Similarly, investigators have produced bispecific antibodies comprising a P-glycoprotein binding moiety and a moiety that binds with a cytotoxic cell. van Dijk et al.,
Int. J. Cancer
44: 738 (1989); Ring et al., international Publication No. WO 92/08802 (1992). The theory behind this approach is that the bispecific antibodies can be used to direct cytotoxic cells to multidrug-resistant cells that express P-glycoprotein.
However, studies have shown that P-glycoprotein is expressed in normal human tissues, such as liver, kidney, adrenal gland, pancreas, colon and jejunum. See, for example, Endicott et al.,
Ann. Rev. Biochem.
58: 137 (1989). Consequently, investigators have warned that “blocking P-glycoprotein action in order to circumvent MDR will also affect the normally expressed P-glycoprotein and this may cause unacceptable side toxic effects.” Childs et al., “The MDR Superfamily of Genes and Its Biological Implications,” in IMPORTANT ADVANCES IN ONCOLOGY 1994, DeVita et al., (eds.), pages 21-36 (J.B. Lippincott Co. 1994). This admonition particularly applies to therapeutic methods that use antibody conjugates consisting of a P-glycoprotein binding moiety and a cytotoxic agent. Therefore, the success of an antibody-directed treatment of MDR tumors will mainly depend upon the ability to kill drug-resistant tumor cells with tolerable side effects to normal tissues of the patient. Efferth et al.,
Med. Oncol.
&
Tumor Pharmacother.
9: 11 (1992).
Thus, an need exists for a method to overcome the MDR phenotype but that also minimizes toxicity to normal tissue.
The emergence of the MDR phenotype also is the major cause of failure in the treatment of infectious diseases. Davies,
Science
264: 375 (1994). In particular, pathogenic bacteria have active drug efflux systems of very broad substrate specificity. Nikaido,
Science
264: 382 (1994), which is incorporated by reference. For example, studies indicate that
Foley & Lardner
Immunomedics Inc.
Nolan Patrick J.
LandOfFree
Polyspecific immunoconjugates and antibody composites for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyspecific immunoconjugates and antibody composites for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyspecific immunoconjugates and antibody composites for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2990968